Vidac Pharma Holding (STU:T9G) Research & Development: €0.52 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:T9G Vidac Pharma Holding PLC STU:T9G
21 GF Score
Price €0.41
! 2 Warning Signs
View Full Analysis

What is Vidac Pharma Holding Research & Development?

Vidac Pharma Holding STU:T9G +1.94% 21 Research & Development is €0.52 Mil as of Jun. 2025. GuruFocus rates STU:T9G with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vidac Pharma Holding's Research & Development for the six months ended in Jun. 2025 was €0.36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was €0.52 Mil.

Vidac Pharma Holding  (STU:T9G) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vidac Pharma Holding Research & Development Related Terms

Vidac Pharma Holding Research & Development Historical Data

* Premium members only.

The historical data trend for Vidac Pharma Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding Research & Development Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Research & Development
0.00 0.22 0.28 0.26

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial 0.09 0.18 0.09 0.16 0.36
STU:T9G
21GF Score
Vidac Pharma Holding PLC STU:T9G
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vidac Pharma Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.52 Mil mean?
Vidac Pharma Holding (STU:T9G) has a Research & Development of €0.52 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vidac Pharma Holding and its competitors.
Is Vidac Pharma Holding's Research & Development too high?
Vidac Pharma Holding's current Research & Development is €0.52 Mil. Overall, Vidac Pharma Holding has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Vidac Pharma Holding's Research & Development compare to VRTX and REGN?
Vidac Pharma Holding's Research & Development of €0.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vidac Pharma Holding and its competitors. Vidac Pharma Holding's current Research & Development is €0.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vidac Pharma Holding stock overvalued right now?
Vidac Pharma Holding (STU:T9G) has a current Research & Development of €0.52 Mil. The current Research & Development is €0.52 Mil. Vidac Pharma Holding's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vidac Pharma Holding (STU:T9G), the current Research & Development is €0.52 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vidac Pharma Holding Business Description

Other Exchanges T9G:Germany
Address 20-22 Wenlock Road, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company's research targets the modification of the tumor microenvironment to inhibit cancer cell growth by selectively affecting metabolic checkpoints in cancer cells without harming normal tissue. Its drug pipeline includes candidates such as VDA-1102 ointment, VDA-1102 IV, and VDA-1275, which are designed to treat conditions like Actinic Keratosis and Cutaneous T-cell Lymphoma. Vidac Pharma operates internationally with headquarters in London and aims to treat cancer through novel chemical entities.
21GF Score

Get the complete analysis for STU:T9G

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price